Navigation Links
Northwest Secures US$4.0 Million in Debt Financing
Date:5/9/2008

BETHESDA, Md., May 9 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO), today announced that Al Rajhi Holdings W.L.L. ("Al Rajhi") has entered into an agreement, executed on May 6 2008, to provide NWBT with debt financing in the amount of US$4.0 million (the "Loan").

Under the terms of the Loan, Northwest will receive US$4.0 million in return for an unsecured promissory note in the principal amount of US$4,240,000 (reflecting an original issue discount of six percent, or US$240,000). The Loan has a term of six months. Al Rajhi may elect to have the original issue discount amount paid at maturity in common stock of NWBT, at a price per share equal to the average closing price of NWBT's common stock on the NASD Over The Counter Bulletin Board over the ten trading days prior to the execution of the Loan agreement.

The Directors of the Company consider, having consulted with the Company's Nominated Adviser, Collins Stewart Europe Limited, that the Loan is fair and reasonable in the circumstances insofar as the Company's shareholders are concerned. In giving its advice to the Directors, Collins Stewart Europe Limited relied on their commercial assessment.

Alton L. Boynton, Chief Executive Officer of NWBT said:

"We are delighted to have secured this Loan from Al Rajhi. Since investing in our IPO on AIM in June 2007, Al Rajhi has accumulated a significant stake in Northwest and currently holds in excess of ten per cent of our issued and outstanding common stock. We appreciate their support for the Company and our DCVax(R) technology. The Loan will enable us to continue moving our programs forward aggressively, with minimal dilution for existing shareholders."

About NWBT

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, with limited toxicity, on a cost-effective ba
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
2. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
3. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
4. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
5. D-Pharm Secures Funding From Israels Chief Scientists Office
6. Aerovance Secures $20 Million in Debt Financing
7. Amarin Secures Global Intellectual Property Rights for Lipid Programs
8. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Taligen Therapeutics Secures Series B Financing
11. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
(Date:9/22/2014)... it is to stop bleeding, are very simple. They ... the physical environment around them, researchers at Emory and ... with greater stiffness by increasing their stickiness, the degree ... components of the clotting system, the researchers found. , ... in that they are able to sense the physical ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Platelets modulate clotting behavior by 'feeling' their surroundings 2
... Texas, Jan. 5, 2012  Healthpoint Biotherapeutics today announced that ... Robert Bancroft, Executive Vice President, Strategic and Commercial Development, ... products and its R&D pipeline at the upcoming J.P. ... January 9th, at 9:30 am (PST) at the Westin ...
... Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis company, today ... presentation at the 5 th Annual OneMedForum San ... Francisco, Calif., January 9-12, 2012. The company ... beginning at 10:00 a.m. Pacific Time.  The presentation will ...
... 5, 2012  ZyGEM Corp. Ltd., a developer and ... DNA and other nucleic acids, and the US ... today announced the signing of a Cooperative Research ... simplified sample processing solutions for biothreat agents.  The ...
Cached Biology Technology:WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 3
(Date:9/23/2014)... times more carbon than the atmosphere and small ... big effect on atmospheric greenhouse gas concentrations. A ... Change concludes that climate warming does not ... carbon storage, despite increases in ecosystem productivity. ... Research Ecologist Dr. Christian Giardina, with the agency,s ...
(Date:9/23/2014)... temperature on insects to predict how climate change will ... shows for the first time that insects, fear of ... fast they grow. , "In other words, it,s less ... that shape the growth, survival and distribution of insects." ... an Arctic postdoctoral researcher at Dartmouth. , The ...
(Date:9/23/2014)... Eureka Therapeutics, Inc. announced today that the Company has ... new funding will be used to expand the Company,s ... clinical development. New investor Yuan Capital led the round, ... including Acorn Campus Ventures, Suma Venture and Harbinger Venture ... and development of fully-human antibodies engineered to mimic the ...
Breaking Biology News(10 mins):Study helps assess impact of temperature on belowground soil decomposition 2Insects' fear limits boost from climate change, Dartmouth study shows 2
... SAN DIEGO, Calif. (March 10, 2009)Attempts to treat ... patients with below-the-knee angioplasty are still thwarted by ... site of angioplasty or stenting), the need for ... disease, leading to tissue death (gangrene) and amputation. ...
... SAN DIEGO, Calif. (March 10, 2009)The use of common ... (ABI)along with traditional risk scoring systemssuch as the Framingham ... in thousands of individuals who are not originally thought ... say researchers at the Society of Interventional Radiology,s 34th ...
... March 9 Explorations Group Inc. (OTC Bulletin ... letter of intent to acquire Daniel R. Smith & Associates, ... total of $4.2 million to be paid in a combination ... Intent, EXGI President David Coriaty stated "the acquisition of DRSA ...
Cached Biology News:Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3Simple test helps predict heart attack risk 2Simple test helps predict heart attack risk 3Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company 2
...
Contains L-glutamine...
... 140kDa GenBank Accession ... amino acids 926-941 (DKKVKPPFIPTIRGRE) of human PRK2. ... Quality Assurance Routinely evaluated by ... Stability 1 year at ...
...
Biology Products: